The University of Chicago Medical Center (Ucmc)
Chicago, Illinois 60637
9 studies enrolling now · 15 studies all time
What they study most
Acute GVHD, Acute-graft-versus-host Disease, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of Lung, Adenocarcinoma of the Stomach, Advanced Solid Tumor, B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL), Carcinoma, Non-Small-Cell Lung, Chronic Graft-versus-host-disease, Chronic Rhinosinusitis (Diagnosis), Chronic Sinusitis
Studies at this site
- A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer — Recruiting now
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) — Recruiting now
- A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer — Recruiting now
- A Study of LY4175408 in Participants With Advanced Cancer — Recruiting now
- FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 — Recruiting now
- A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) — Recruiting now
- Platform Clinical Study for Conquering Scleroderma — Recruiting now
- Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma — Recruiting now
- Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients — Running, not enrolling
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors — Running, not enrolling
- Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2) — Completed
- Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma — Available (expanded access)
- NM32-2668 in Adult Patients With Selected Advanced Solid Tumors — Stopped early
- A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) — Stopped early
- A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy — Completed